ANIP FY 2021 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

FY 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$216M+3.7% YoY

Gross Profit

$116M53.5% margin

Operating Income

-$40M-18.4% margin

Net Income

-$43M-19.7% margin

EPS (Diluted)

$-3.40

Cash Flow

Operating Cash Flow

$3M

Free Cash Flow

-$20M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$772M

Total Liabilities

$413M

Stockholders' Equity

$359M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$216M	$208M	+3.7%
Gross Profit	$116M	$121M	-4.8%
Operating Income	-$40M	-$16M	-148.5%
Net Income	-$43M	-$23M	-88.9%